Table 1.
Sorted ALDH1 Expressing Cells Show an Increased Capacity for MRT PDX Propagation
| Passage | Cell Type | No. of Injected Cells | Frequency of Engrafted Tumors | Total Frequency of Engrafted Tumors | CSC Frequencya (95% CI) |
|---|---|---|---|---|---|
| Primary (MRT-02)b | ALDH1+ | 1,000 | 4/4 | 4/4 | >1/1,000 (1,562, 1) |
| ALDH1− | 1,000 | 0/4 | 0/4 | – | |
| P3 (MRT-01)c | US | 2,000 | 1/1 | 1/5 | 1/3,915 (25,830, 593) |
| 1,000 | 0/2 | ||||
| 500 | 0/2 | ||||
| ALDH1+ | 2,000 | 2/2 | 4/6 | 1/745 (2,201, 252) | |
| 1,000 | 2/2 | ||||
| 500 | 0/2 | ||||
| ALDH1− | 2,000 | 0/2 | 0/6 | – | |
| 1,000 | 0/2 | ||||
| 500 | 0/2 | ||||
| P12 (MRT-01)c | US | 500 | 3/5 | 7/9 | 1/242 (61,495) |
| 100 | 4/4 | ||||
| ALDH1+ | 500 | 3/3 | 11/11 | >1/50 (58, 1) | |
| 100 | 4/4 | ||||
| 50 | 4/4 | ||||
| ALDH1− | 500 | 2/3 | 2/11 | 1/773 (2,976, 201) | |
| 100 | 0/4 | ||||
| 50 | 0/4 |
Sorted ALDH1-expressing cells show an increased capacity for MRT PDX propagation in primary, early (P3), and late (P12) passages.
a
In the comparison between ALDH− and ALDH+ PDX passages: p = 0.0285 in primary, p = 0.002 in P3, and p < 0.001 in P12; Fisher exact test.
b
Primary (MRT-02), cells obtained from primary MRT of kidney (RTK) of patient 2.
c
P3 and P12 (MRT-01), cells obtained from MRT PDX of patient 1.